South Africa Liver Diseases Therapeutics Market Report 2022 to 2030

South Africa Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the South Africa Liver Disease Therapeutics market will reach a value of $257 Mn from $150 Mn in 2022, growing at a CAGR of 6.9 % during 2022-30. Liver Disease Therapeutics in South Africa is dominated by a few domestic pharmaceutical companies such as Aspen Pharmacare, Adcock Ingram, and Pharma Dynamics. The Liver Disease Therapeutics market in South Africa is segmented into different types of disease and different therapy types. Some of the major factors affecting the South Africa Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10ZAPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: South Africa AUTHOR: Dr. Vishwa Modhia

Buy Now

South Africa Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the South Africa Liver Disease Therapeutics market will reach a value of $257 Mn from $150 Mn in 2022, growing at a CAGR of 6.9 % during 2022-30.

South Africa is an upper-middle-income, developing country located at the southern tip of the African continent. According to the World Health Organization, the prevalence of hepatitis B in South Africa is estimated to be between 5-7%, while the prevalence of hepatitis C is estimated to be between 0.1-0.3%. According to the latest WHO data published in 2020 Liver Disease Deaths in South Africa reached 9,013 or 1.98% of total deaths. The age-adjusted Death Rate is 18.41 per 100,000 population ranks South Africa 95^th in the world. South Africa's government spent 4.6% of its GDP on healthcare in 2020.

South Africa Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Non-alcoholic fatty liver disease (NAFLD) is another major health issue in South Africa, with an estimated prevalence of up to 30% in the general population and up to 75% in people with diabetes or obesity. Chronic liver disease patients may also be eligible for specialised care through the South African Society of Gastroenterology, which offers diagnostic tests, specialist consultations, and liver transplant services. These aspects could boost South Africa Liver Disease Therapeutics market.

Market Restraints

Greater knowledge and education regarding liver disease prevention and management are needed in South Africa, especially among high-risk populations such those with diabetes or obesity, as well as measures to enhance access to treatment and improve patient outcomes. These factors may deter new entrants into the South Africa Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Aspen Pharmacare: Aspen Pharmacare is a South African pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer, hepatitis B and C, and liver cirrhosis
Adcock Ingram: Adcock Ingram is a South African pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer, hepatitis B and C, and liver cirrhosis
Cipla Medpro: Cipla Medpro is a South African pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B
Pharma Dynamics: Pharma Dynamics is a South African pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer, hepatitis B and C, and liver cirrhosis
Teva Pharmaceuticals: Teva Pharmaceuticals is a global pharmaceutical company with a strong presence in South Africa. The company produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B

Recent Notable Updates

August 2022: Aspen Pharmacare Holdings Limited (APN), a global multinational speciality pharmaceutical company listed on the JSE Limited, is pleased to announce that one of its wholly-owned South African subsidiaries, Aspen SA Operations (Pty) Limited, has entered into a ten-year agreement ("the Agreement") with Serum Institute of India Pvt Ltd ("the Serum Institute"), the world's largest vaccine producer, for Aspen SA Operations to manufacture, market, and distribute four Aspen-branded routine vaccines. The terms of the agreement for the vaccines, include the Pneumococcal Vaccine, Rotavirus Vaccine, Polyvalent Meningococcal Vaccine, and Hexavalent Vaccine.

Healthcare Policies and Reimbursement Scenarios

In South Africa, the regulation and reimbursement of liver therapeutics are overseen by the South African Health Products Regulatory Authority (SAHPRA) and the National Health Insurance (NHI) system, respectively. SAHPRA is responsible for regulating the safety, efficacy, and quality of liver therapeutics before they can be marketed and used in South Africa. The reimbursement process is managed by the NHI, which determines which therapies are eligible for reimbursement and the conditions under which they will be covered.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.